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Tenofovir, a widely prescribed antiretroviral medication for
treatment of HIV-1 infection, is infrequently associated with
renal dysfunction and biopsy findings of acute tubular
necrosis. We examined the clinical and pathological findings
in 13 cases of tenofovir nephrotoxicity (7 men and 6 women,
mean age of 51.1±9.6 years). Patients received tenofovir
therapy for a mean of 19.6 months (range, 3 weeks to 8 years;
median 8 months). Nine patients presented with acute
kidney injury, and four had mild renal insufficiency with
subnephrotic proteinuria. Mean baseline serum creatinine
was 1.3±0.3mg/dl, reaching 5.7±4.0mg/dl at the time of
biopsy, with mean proteinuria of 1.6±0.3 g/day. Glycosuria
was documented in seven patients, five of whom were
normoglycemic. Renal biopsy revealed toxic acute tubular
necrosis, with distinctive proximal tubular eosinophilic
inclusions representing giant mitochondria visible by light
microscopy. Electron microscopy showed mitochondrial
enlargement, depletion, and dysmorphic changes. Clinical
follow-up after tenofovir discontinuation was available for
11 of 13 patients (mean duration 13.6 months). Significant
recovery of renal function occurred in all patients, including
four who required transient hemodialysis. Our study shows
that tenofovir nephrotoxicity is a largely reversible form of
toxic acute tubular necrosis targeting proximal tubules and
manifesting distinctive light microscopic and ultrastructural
features of mitochondrial injury.
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Tenofovir disoproxil fumarate (TDF) is an acyclic nucleotide
analog reverse transcriptase inhibitor approved for the
treatment of human immunodeficiency virus 1 (HIV-1)
and hepatitis B infections. TDF is widely prescribed, and is an
integral part of each of the four ‘preferred’ regimens for
treatment of HIV-1 in antiretroviral-naı¨ve adults and
adolescents.1 TDF has gained popularity because of its
convenient dosing schedule, antiviral efficacy, and relatively
favorable side-effect profile, making it one of the most widely
prescribed antiretroviral drugs for the treatment of HIV-1.2
Closely related drugs, including adefovir and cidofovir, are
no longer used for HIV-1 infection because of their high
incidence of renal toxicity.3,4 In contrast, TDF appears to be
generally well tolerated, with minimal nephrotoxicity repor-
ted in early studies.5 Postmarketing safety data covering
455,392 person-years of TDF exposure showed a renal serious
adverse event in only 0.5% of patients and graded elevations
in serum creatinine in 2.2% of patients.6 Although relatively
uncommon, TDF has been linked to the development of
proximal tubular dysfunction,7 Fanconi syndrome, and acute
kidney injury (AKI). Reports of Fanconi syndrome and acute
renal failure attributed to TDF have been published in
multiple individual case reports and small series.8–13
Although several patients underwent renal biopsy, only one
previous series has examined the morphological features of
TDF nephrotoxicity.14 We present the first biopsy-based
series of TDF-associated renal dysfunction, including pre-
senting clinical features and outcome.
RESULTS
A total of 13 cases of TDF nephrotoxicity, a toxic form of
acute tubular necrosis related to treatment with TDF, were
identified from the archives of the Columbia University Renal
Pathology Laboratory between October 2001 and January
2010. Four additional potential cases were excluded, includ-
ing two in which the tubular injury more likely related to
prerenal azotemia and hypovolemia, one patient who had
received a liver transplant for viral hepatitis and was on other
nephrotoxic medications including cyclosporine, and one in
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which the patient was also taking cidofovir, a chemically
related drug with established renal toxicity.4
Patient demographics and clinical characteristics are
presented in Table 1. The cohort of 13 patients had a
male:female ratio of 7:6 and included seven African-
American, five Caucasian, and one Hispanic patient. The
mean age at biopsy was 51.1±9.6 years (range, 38–68 years).
All patients had HIV-1 infection, including two patients
who were coinfected with hepatitis C virus and two who
had a history of coinfection with hepatitis B virus but
no detectable hepatitis B viremia at the time of biopsy.
A complete list of antiviral medications for each patient
is presented in Table 1. Information on viral load and/or
CD4 count was available for 10 of 13 patients. All 10 patients
had undetectable viral load, with mean CD4 count of
339±270 cells/ml (range, from 11 to 728 cells/ml). The
duration of TDF therapy at the time of biopsy ranged from
3 weeks to 8 years, with a mean of 19.6±26.1 months and
a median of 8 months.
Indications for renal biopsy included AKI in nine patients
and milder reductions in renal function accompanied by
proteinuria (X1 g/day) in four patients. Serum creatinine
measurements are provided in Table 1. Among the 13
patients, 7 had already been taking TDF for some period of
time when the ‘baseline’ creatinine was recorded. The remain-
ing six patients had not yet commenced treatment with
TDF. Mean baseline serum creatinine was 1.3±0.3mg/dl,
ranging from 0.8 to 1.8mg/dl. TDF requires renal dosing
when glomerular filtration rate is below 50ml/min, a
condition met by three patients in this series. Data regarding
TDF dosage was available for only one of these patients who
was receiving an appropriately adjusted dose based on the
level of renal insufficiency. The mean serum creatinine at the
time of biopsy was 5.7±4.0mg/dl (range, 1.1–13mg/dl).
Proteinuria was quantitated by 24-h collection or by dipstick
in all of the 11 patients who were not anuric at the time of
biopsy. Among the seven patients with a 24-h urine
collection, the mean proteinuria was 1.6±0.3 g/day (range,
Table 1 | Demographics, clinical characteristics, and follow-up
1 2 3 4 5 6 7 8 9 10 11 12 13
Age/gender 40/M 51/F 63/M 53/M 68/F 52/F 56/M 38/M 41/F 55/M 60/M 57/F 58/F
Race AA AA AA AA AA C Hisp C C C C AA AA
Viral infections HIV,
HBV
(tx’d)
HIV HIV HIV HIV HIV HIV HIV,
Anti-
HBc+
HIV HIV HIV HIV,
HCV
HIV,
HCV
HIV control VLo50;
CD4 417a
VLo50;
CD4 75a
NA VLo50;
CD4 82a
VLo50;
CD4 11a
‘Good
control’
VLo50;
CD4 728a
VLo50 ‘Good
control’
VLo50;
CD4 4500a
VLo50 VLo50;
CD4 275a
VLo50;
CD4 624a
Antiviral
medications
TDF,
FTC,
ATV,
RTV
TDF,
FTC
TDF,
FTC,
EFV
TDF,
DDI,
ATV,
RTV
TDF,
DDI,
LPV
TDF,
FTC,
EFV
TDF,
LPV,
RTV
TDF,
AZT,
RTV
TDF,
FTC,
EFV
TDF,
DRV,
RTV
TDF,
FTC,
LPV,
RTV
TDF,
NVP,
LPV,
RTV
TDF,
FTC,
ATV,
RTV
Duration of
TDF Rx (months)
48 24 8 6 6 8 0.75 24 12 7 96 12 4
Diabetes No Yes Yes No No Yes No No No No No No No
Hypertension No No Yes No No Yes No No No Yes No No No
Baseline SCr (mg/dl)/
(months before bx)
1.4 (1) 1.8 (5) 1.5 (1) 1.2 (6) 1.6 (2) 1.2 (8) 1.0 (0.75) 1.0 (5) 0.8 (12) 1.3 (12) 1.6 (12) 1.3 (4) 1.0 (4)
Findings at the time of biopsy
Indication
for biopsy
Prot AKI AKI Prot AKI AKI AKI Prot Prot AKI AKI AKI AKI
SCr (mg/dl) 1.7 6.3 5.5 2.1 6.8 4.6 13 1.6 1.1 13 9 4.8 4.9
Proteinuria 1.86
g/day
2.07
g/day
1+ 1.5
g/day
3+ 1+ Anuria 1.3
g/day
1.2
g/day
2
g/day
Anuria 1.47
g/day
2+
Hematuria No Microscopic No No Microscopic No Anuria No No No Anuria No No
Glycosuria 1+ 3+ Neg 1+ 1+ 3+ Anuria 1+ Neg 250mg/dl Anuria Neg Neg
Serum glucose 106 138 Normal Normal 76 170 Normal 94 Normal Normal Normal 125 89
Follow-upb
Required HD? No Yes, for
4 months
Yes, for
1 month
NA No No Yes, for
1 month
No No Yes Yes, for
1 month
No No
Duration (days) 158 144 34 NA 161 1729 170 1183 146 NA 131 309 338
SCr (mg/dl) 1.3 1.2 Off HD NA 1.6 1.6 1.4 0.8 0.8 NA 1.94 1.2 1.2
Proteinuria 66mg/dl NA Neg NA NA Neg Neg Neg 25mg/dl NA NA Neg Trace
Abbreviations: AA, African American; AKI, acute kidney injury; Anti-HBc+, hepatitis B core antibody positive; ATV, atazanavir; AZT, zidovudine; bx, biopsy; C, Caucasian; DRV,
darunavir; EFV, efavirenz; F, female; FTC, emtricitabine; HBV, hepatitis B virus; HCV, hepatitis C virus; HD, hemodialysis; Hisp, Hispanic; HIV, human immunodeficiency virus;
LPV, lopinavir; M, male; NA, not available; Neg, negative; NVP, nevirapine; prot, proteinuria (X1 g/day); RTV, ritonavir; Rx, treatment; SCr, serum creatinine; TDF, tenofovir
disoproxil fumarate; tx’d, treated; VL, viral load (copies/ml).
aCD4 is measured as cells/ml.
bAll patients were taken off tenofovir therapy, and follow-up duration is calculated from the date of tenofovir discontinuation.
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1.2–2.07 g/day). The remaining four patients had evidence of
1–3þ proteinuria on urinalysis. Glycosuria was detected in
seven patients, five of whom were normoglycemic and two
of whom were hyperglycemic with a history of diabetes.
Microscopic hematuria was present in 2 of 11 patients.
Renal biopsy findings are presented in Table 2. The major
finding in all cases was proximal tubular injury, which ranged
from diffuse and severe (n¼ 11) (Figure 1a) to mild and
localized (‘patchy’; n¼ 2), and was associated with varying
degrees of chronic tubulointerstitial scarring (that is, tubular
atrophy and interstitial fibrosis) (Figure 1b). In 10 of the
13 cases, findings of acute tubular injury predominated,
meriting a diagnosis of toxic acute tubular necrosis. In the
remaining three cases, the findings of chronic injury
predominated, leading to a diagnosis of acute and chronic
tubulointerstitial nephropathy. Additional unrelated pro-
cesses were identified in five cases, including two with
diabetic glomerulosclerosis, two with significant arterione-
phrosclerosis (including subcapsular scarring, ischemic
glomeruli, and at least moderate vascular disease), and one
with resolving postinfectious glomerulonephritis.
The mean number of glomeruli sampled for light micro-
scopy was 20.6, of which on average 22.4±24.6% (range,
0–71%) were globally sclerotic. Tubular atrophy and inter-
stitial fibrosis involved a mean of 16.9±14.7% of the cortex
sampled (range, 0–50%;p20% in 10 of 13 cases), and vessels
showed mild-to-moderate arteriosclerosis. None of the biopsies
had collapsing focal segmental glomerulosclerosis or tubular
microcysts typical of HIV-associated nephropathy.
The light microscopic findings in TDF nephrotoxicity
broadly resemble changes seen in other forms of toxic ATN
and include luminal ectasia, cytoplasmic simplification and
hypereosinophilia, irregular luminal contours, prominent
nucleoli, and loss of brush border (Figure 1a). A distinctive,
additional finding seen in TDF nephrotoxicity, but not
in other forms of toxic ATN, is prominent eosinophilic
intracytoplasmic inclusions within proximal tubular epi-
thelial cells. These structures, which stain brightly with
hematoxylin and eosin and can appear as large as tubular
nuclei, represent giant mitochondria that are visible at the
light microscopic level (Figure 1c). The tubular inclusions
can also be identified by their fuchsinophilic appearance with
trichrome stain (Figure 1d), but do not stain with periodic
acid-Schiff or silver stains.
The major ultrastructural findings were acute proximal
tubular degenerative changes and dysmorphic mitochondria,
which were identified in 12 of 13 cases (Figure 2). Mitochondria
varied widely in size and shape, ranging from small and rounded
to markedly enlarged and swollen with irregular contours
(Figure 2a). In some cells, mitochondria approached the size
of the nucleus (Figure 2b and c). Many of the enlarged mito-
chondria displayed prominent clumping, loss, and disorientation
of cristae, which frequently were only identified along the inner
mitochondrial membrane (Figure 2d). In some proximal tubular
epithelia, the number of mitochondria was markedly reduced,
consistent with mitochrondrial depletion.
Ultrastructural evaluation of glomeruli revealed a rare
endothelial tubuloreticular inclusion in 2 of 13 cases, and
only mild podocyte foot process effacement (mean, 20%,
range, 5–50%). Immune-type electron-dense deposits were
identified in a single case (case no. 3) and were attributed to
resolving postinfectious glomerulonephritis with corresponding
mesangial positivity for immunoglobulin M (IgM), C3, C1,
kappa, and lambda by immunofluorescence.
Clinical follow-up was available for 11 of 13 patients
(Table 1; Figure 3). The mean duration of follow-up was
19.6±26.1 months (range, 1.1–56.8 months), and TDF
therapy was discontinued at the time of renal biopsy in all
Table 2 | Biopsy findings
1 2 3 4 5 6 7 8 9 10 11 12 13
Light microsocpy
Acute tubular
injury
Diffuse Diffuse Diffuse Patchy,
mild
Diffuse Diffuse Diffuse Patchy,
mild
Diffuse Diffuse Diffuse Diffuse Diffuse
Global GS 3/27 1/5 3/6 2/42 15/21 5/32 1/9 2/7 0/20 0/7 2/22 1/23 29/44
T/IF % 10% 20% 10% 15% 30% 50% 0% 10% 5% 10% 15% 5% 40%
Mitochondria
on LM?
Yes No Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes
Arteriosclerosis Mild Moderate Mild Mild Moderate Mild Mild Mild Mild Moderate Moderate Mild Moderate
to severe
Primary
diagnosis
Toxic
ATN
Toxic
ATN
Toxic
ATN
A/C
TIN
Toxic
ATN
A/C
TIN
Toxic
ATN
A/C
TIN
Toxic
ATN
Toxic
ATN
Toxic
ATN
Toxic
ATN
Toxic
ATN
Secondary
diagnosis
None Diffuse
DGS, mod
Res. PIGN None ArtNS Diffuse
DGS, mild
None None None None None None ArtNS
Electron microscopy
Dysmorphic
mitochondria
Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes
TRIs? No No No No No No No No No No No Yes Yes
FPE 15% 30% 30% 20% 20% 50% 5% 5% 30% 10% 10% 20% 10%
Abbreviations: A/C TIN, acute and chronic tubulointerstitial nephropathy; ArtNS, arterionephrosclerosis; ATN, acute tubular necrosis; DGS, diabetic glomerulosclerosis;
FPE, foot process effacement; GS, glomerulosclerosis; LM, light microscopy; Res. PIGN, resolving post-infectious glomerulonephritis; T/IF, tubular atrophy and interstitial
fibrosis; TRIs, endothelial tubuloreticular inclusions.
Kidney International (2010) 78, 1171–1177 1173
LC Herlitz et al.: Tenofovir nephrotoxicity o r ig ina l a r t i c l e
patients. Complete recovery of renal function to ‘baseline’
levels was seen in six patients (patients 1, 2, 5, 8, 9, and 12)
who had a mean follow-up time of 11.5±13.6 months
(range, 4.7–38.9 months), including patient no. 2 who was
dialysis dependent for 4 months. Among these six patients,
the mean biopsy and follow-up serum creatinine were
3.72±2.56 and 1.15±0.31mg/dl. Five additional patients
exhibited partial recovery of renal function but did not return
to baseline within the mean follow-up period of 13.6±21.5
months (range, 1.1–56.8 months; patients 3, 6, 7, 11, and 13).
Serum creatinine values were available for four of the five
patients with partial recovery, and among these four patients,
the mean peak and follow-up serum creatinine levels were
5.6±3.8 and 1.5±0.3mg/dl, respectively. Of note, three of
the five patients required dialysis, each for B1 month.
Patient 3 is known to have recovered sufficient renal function
to discontinue dialysis after 1 month, but no further follow-
up is available. Follow-up data on proteinuria is available for
eight patients. As evaluated by urine dipstick, five patients
were negative for proteinuria and one patient showed trace
protein. Protein excretion was quantified in two patients,
who had urine protein concentrations of 66 and 25mg/dl,
respectively.
Outcomes can also be viewed in terms of clinical
presentation and indication for biopsy. Of the four patients
who presented with AKI and required dialysis, there was one
complete recovery and two substantial partial recoveries
(decline in creatinine from 13 and 9 to 1.4 and 1.94mg/dl,
respectively). A fourth patient discontinued dialysis at 1 month,
but additional follow-up is not known. Of the four patients
a b
c d
Figure 1 | Light microscopic findings in tenofovir disoproxil fumarate (TDF) nephrotoxicity. (a) Proximal tubules exhibit diffuse
and severe acute degenerative changes including luminal ectasia, cytoplasmic simplification, irregular luminal contours, loss of brush
border, and focal apoptosis with epithelial desquamation, with adjacent interstitial edema. These findings are typical of toxic acute tubular
necrosis (hematoxylin and eosin,  400). (b) A low-power view demonstrates tubular simplification, as well as more chronic tubular atrophy
and interstitial fibrosis. These light microscopic findings are consistent with an acute and chronic tubulointerstitial nephropathy (periodic
acid-Schiff,  200). (c) A characteristic feature of TDF nephrotoxicity is eosinophilic intracytoplasmic inclusions within proximal tubular
epithelial cells, corresponding to the giant mitochondria seen ultrastructurally (hematoxylin and eosin,  600). (d) The proximal tubular
inclusions stain red (or fuchsinophilic) with trichrome stain ( 1000).
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who presented with AKI but did not require dialysis, there
were two complete and two substantial partial recoveries
(decline in creatinine from 4.6 and 4.9 to 1.6 and 1.2mg/dl,
respectively). All three patients biopsied for proteinuria and
mild renal dysfunction made a full recovery to ‘baseline’ serum
creatinine with resolution of proteinuria.
DISCUSSION
Multiple case reports and small series have demonstrated the
potential for TDF to cause renal injury. Compared with
existing series in the literature in which the mean peak
creatinine was 1.96, 1.98, and 3.9mg/dl,10–12 patients in our
cohort had higher serum creatinine at the time of renal
biopsy (mean 5.7±4.0mg/dl), likely reflecting the relatively
high clinical threshold to perform this procedure. Consistent
with previous reports, patients in our cohort displayed
subnephrotic proteinuria and proximal tubular dysfunction
including normoglycemic glycosuria. Information regarding
additional parameters of Fanconi syndrome was not available
in most patients at the time of biopsy. Patients had been
taking TDF for a mean of 19.6±26.1 months and a median
of 8 months (range, 3 weeks to 8 years). HIV viral control
was good in all patients with available data.
In the previously published analysis of postmarketing
safety data for TDF,6 a multivariate analysis identified
advanced age, low body weight, elevated creatinine before
starting TDF therapy, and lower CD4 count as risk factors for
the development of increased creatinine during TDF use. Our
patient population showed a mean age of 51.1 years and a
mean CD4 count of 339±270 cells/ml, as compared with a
mean age of 42 years and a mean CD4 count of 215 cells/ml in
the postmarketing safety data. All but three of our patients
a b
c d
Figure 2 |Ultrastructural findings in tenofovir disoproxil fumarate (TDF) nephrotoxicity. (a) A low-magnification field demonstrates
the wide range in size and shape of mitochrondria within proximal tubular epithelial cells ( 5000). (b) Markedly enlarged mitochondria
are interspersed with normal-sized mitochrondria in proximal tubular cells. One cell is undergoing degeneration with shedding of
cytoplasmic fragments into the tubular lumen ( 5000). (c) At higher magnification, the enlarged mitochrondria are largely devoid of
cristae. In contrast, cristae are easily identified in adjacent, normal-sized mitochondria ( 8000). (d) Abnormalities in the number and
distribution of mitochondrial cristae are best appreciated at high magnification. In this field, there is focal loss of cristae, as well as clustering
of residual cristae at the peripheral mitochrondrial membrane ( 20,000).
Kidney International (2010) 78, 1171–1177 1175
LC Herlitz et al.: Tenofovir nephrotoxicity o r ig ina l a r t i c l e
were over the age of 50 years, underscoring the risk of greater
age. Thus, as patients with HIV-1 infection are living longer,
the risk of this toxicity is likely to increase. Interestingly, the
concurrent use of ‘boosted’ protease inhibitors lopinavir and
ritonavir, which had been suggested to be a risk factor in
previous reports,12 was not shown to increase risk in the
postmarketing safety data. At least one of these agents was
used in 9 of our 14 patients.
Clinical outcomes in our series are consistent with
previous series showing significant improvement in renal
dysfunction after TDF cessation, and demonstrate the
potential for renal recovery from TDF nephrotoxicity, despite
the presence of profound renal dysfunction requiring as long
as 4 months of renal replacement therapy. In a small case
series and literature review, Zimmerman et al.12 identified
5 of 27 patients with incomplete recovery from TDF toxicity.
In our series, six patients achieved complete recovery of
renal function, and the remaining five patients with available
data showed partial but significant recovery. Although these
outcomes are encouraging, almost half of our patients with
TDF nephrotoxicity were left with mild chronic kidney
disease, underscoring the importance of close monitoring of
at-risk patients receiving TDF therapy.
The current report provides a detailed histological
description of the light microscopic and ultrastructural
abnormalities in TDF toxicity. Light microscopy revealed
acute proximal tubular injury in all cases, with varying
degrees of chronic tubulointerstitial scarring. We are the first
to report the light microscopic finding of eosinophilic
inclusions within the cytoplasm of proximal tubular
epithelial cells; these ‘inclusions’ represent giant mitochon-
dria that were identifiable by light microscopy in 12 of 13
cases. Electron microscopy revealed a spectrum of distinctive
mitochondrial abnormalities involving mitochondrial num-
ber, size, shape, and cristal patterns, resembling the changes
in other mitochondrial DNA (mtDNA) depletion syndromes.
Mild variation in mitochondrial size and shape can be seen in
normal kidney; however, the mitochondrial depletion,
marked variation in size, and the highly irregular shapes
seen in TDF toxicity fall well outside the normal spectrum.
Importantly, in many types of acute tubular injury,
mitochondria can display prominent swelling and expansion
of the mitochondrial matrix by electron lucent aqueous fluid,
which in turn disrupts the cristal architecture. In TDF
toxicity, the expanded mitochondrial matrix retains its
normal electron density, and the cristae display abnormal
numbers and orientations that cannot be attributed to
mechanical distortion by ballooning degeneration. The light
microscopic and ultrastructural findings support the hypoth-
esis that TDF toxicity primarily targets mitochondria, and
that as a result, the pathological changes are most prominent
in the proximal tubules, leading to histological findings of
toxic ATN and clinical findings of proximal tubular
dysfunction with Fanconi syndrome.
Nucleotide reverse transcriptase inhibitors are known to
impair mitochondrial replication by inhibition of DNA
polymerase-g.15 The potential role of mitochondrial toxicity
in the mediation of TDF nephrotoxicity was studied by
Cote et al.,14 who reported dysmorphic mitochondria at the
ultrastructural level, similar to reported changes following
adefovir administration,3 but were unable to demonstrate
mtDNA depletion that could be directly attributed to the use
of TDF. mtDNA depletion has been demonstrated in animal
models of TDF toxicity. TDF-exposed rats show low mtDNA
copy number and impaired expression of mitochondrial-
encoded proteins (such as cytochrome c oxidase 1; COX 1),
but not nuclear-encoded COX IV.16 Additional support for
TDF mitochondrial toxicity comes from Kohler et al., who
studied TDF exposure in a murine HIV transgenic model.
Using laser capture microdissection to specifically isolate
renal proximal tubules, they found that TDF exposure
resulted in decreased proximal tubular mtDNA content and
corresponding mitochondrial ultrastructural abnormalities.17
The current series expands the literature on TDF toxicity,
further defines the histological and ultrastructural findings,
and emphasizes the need for early recognition of this entity,
which in many cases is only partially reversible. Current
guidelines from the HIV Medicine Association of the
Infectious Disease Society of America recommend that
patients receiving TDF, who have a glomerular filteration
rateo90ml/min per 1.73m2, other comorbid diseases (such
as diabetes or hypertension), or who are receiving ritonavir-
boosted protease inhibitors, be screened at least biannually
for measurements of renal function, serum phosphorus,
proteinuria, and glycosuria.18 Efforts have been made to
identify subsets of patients at risk for developing TDF renal
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Figure 3 |Changes in serum creatinine after discontinuation
of treatment with tenofovir from the time of renal biopsy
to the last follow-up available. Red lines indicate patients
who required transient renal replacement therapy, blue lines
indicate patients who were biopsied for proteinuria and
mild renal insufficiency, black dashed lines represent patients
with acute kidney injury who did not require dialysis, and the
solid black line represents change in mean serum creatinine
between the two time points. Patient no. 3 is not included
in this figure because no quantitative assessment of renal function
was available.
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toxicity. One study found a strong association between TDF-
induced tubular dysfunction and a polymorphism in ABCC2,
the gene encoding multidrug resistance protein 2, which is in
part responsible for the efflux of tenofovir from proximal
tubular cells.19 The possibility of reducing the renal toxicity
of TDF by administering other drugs that regulate intracel-
lular transport and bioavailability of tenofovir is an
intriguing strategy. In their review of the nephrotoxic effects
of HAART,20 Izzedine et al. noted that probenecid is an
effective inhibitor of hOAT1, the transporter primarily
responsible for tenofovir entry into tubular cells. The
potential use of such medications to mitigate or prevent
TDF nephrotoxicity deserves further study.
In summary, we present a renal biopsy series of 13 patients
with TDF nephrotoxicity. The histological and ultrastructural
findings demonstrate a distinctive pattern of proximal
tubular injury characterized by severe mitochondrial damage,
supporting a mechanism of drug-induced mitochondrial
toxicity. Despite the presence of severe renal failure, in some
cases requiring renal replacement therapy, outcomes were
quite good after discontinuation of TDF. Careful monitoring
of renal function for prompt detection of TDF nephrotoxicity
is critically important to ensure timely drug withdrawal
before the development of irreversible tubulointerstitial
injury. Although TDF nephrotoxicity appears to be a
relatively rare complication, it is a potentially serious one,
warranting careful screening of patients at risk.
MATERIALS AND METHODS
A total of 17 cases of tubular injury in the setting of TDF use were
identified retrospectively from the archives of the Columbia
University Renal Pathology Laboratory between October 2001
(when TDF was granted Food and Drug Administration approval)
and January 2010. Diagnostic criteria for TDF nephrotoxicity
included (1) documented use of TDF at the time of renal
presentation, (2) pathological findings of acute and/or chronic
tubular injury, (3) an acute decline in renal function, and (4) the
absence of alternative causes of acute renal dysfunction. AKI was
defined as a doubling of serum creatinine.
Renal biopsies were processed according to standard techniques.
All biopsies were stained with hematoxylin and eosin, periodic acid-
Schiff, Masson’s trichrome, and Jones methenamine silver for light
microscopy. Immunofluorescence was performed on 3 mm cryostat
sections with fluorescein isothiocyanate-conjugated polyclonal
antibodies to IgG, IgM, IgA, C3, C1q, kappa, lambda, fibrinogen,
and albumin (Dako, Carpinteria, CA, USA). Electron microscopy
was performed using a JEOL 1011 electron microscope (JEOL,
Tokyo, Japan).
Statistical analysis was performed with Stata (version 10.1;
StataCorp, College Station, TX, USA). Continuous variables were
compared with student t-test and the paired t-test as appropriate,
whereas the categorical variables were compared using the Fisher’s
exact test.
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